文献速递泌尿男性生殖肿瘤

多参数超声对比多参数MRI诊断前列腺癌(CADMUS):一项前瞻性、多中心、配对队列、验证性研究

Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
PubMed 文献 · Lancet Oncol · 2022-01-01

CADMUS研究在英国7家医院前瞻性纳入370例前列腺癌风险患者,配对比较多参数超声与多参数MRI。多参数超声阳性率89%高于MRI的78%,但单独检出PROMIS定义1临床显著癌的比例为26% vs 30%(差值-4.3%)。作者认为多参数超声可作为MRI不可行时的替代首选检查。

要点

  • 多参数超声阳性率89%(272/306)高于多参数MRI的78%(238/306),差值11.1%(95%CI 5.1-17.1)。
  • 多参数超声单独检出PROMIS定义1显著癌26%(66/257),多参数MRI为30%(77/257),差值-4.3%(95%CI -8.3%至-0.3%)。
  • 联合两种检查检出32%(83/257)显著癌,其中6例(7%)仅超声检出、17例(20%)仅MRI检出。

核心结论

  • 多参数超声检出的临床显著前列腺癌比多参数MRI少4.3%,但会使多11.1%的患者被转诊活检。
  • 多参数超声可作为前列腺癌风险患者的一线替代检查,尤其当多参数MRI无法进行时。
  • 两种影像均会漏诊对方检出的临床显著癌,联合使用可提高检出率。

研究设计与样本

  • 前瞻性、多中心、配对队列、验证性研究,在英国7家医院开展。
  • 2016年3月15日至2019年11月7日纳入370例≥18岁、PSA升高或直肠指检异常的前列腺癌风险患者。
  • 306例完成多参数超声和多参数MRI,257例接受前列腺穿刺活检。
  • 多参数超声包括B模式、彩色多普勒、实时弹性成像和超声造影。
  • 多参数MRI包括高分辨率T2加权成像、扩散加权成像(高B值1400 s/mm2或2000 s/mm2及表观扩散系数图)和动态对比增强轴位T1加权成像。

主要发现

  • 多参数超声阳性272/306例(89%,95%CI 85-92),多参数MRI阳性238/306例(78%,95%CI 73-82),差值11.1%(95%CI 5.1-17.1)。
  • 阳性检查一致率73.2%(95%CI 67.9-78.1;κ=0.06,95%CI -0.56至0.17)。
  • 257例活检患者中检出任何癌133例(52%,95%CI 45.5-58),PROMIS定义1临床显著癌83例(32%,95%CI 26-38)。
  • 多参数超声单独检出PROMIS定义1癌66/257例(26%,95%CI 21-32),多参数MRI检出77/257例(30%,95%CI 24-36),差值-4.3%(95%CI -8.3%至-0.3%)。
  • 联合检出83/257例(32%,95%CI 27-38)PROMIS定义1癌,其中仅超声检出6/83例(7%,95%CI 3-15),仅MRI检出17/83例(20%,95%CI 12-31),一致率91.1%(95%CI 86.9-94.2;κ=0.78,95%CI 0.69-0.86)。

关键数值与推荐

  • 临床显著癌定义为任何区域Gleason评分≥4+3或任何分级最大癌核心长度≥6 mm(PROMIS定义1)。
  • 阳性病灶定义为Likert评分≥3。
  • 多参数超声阳性率89%(272/306)vs 多参数MRI 78%(238/306),差值11.1%(95%CI 5.1-17.1)。
  • 多参数超声单独检出PROMIS定义1癌26%(66/257)vs 多参数MRI 30%(77/257),差值-4.3%(95%CI -8.3%至-0.3%)。

临床怎么用

  • 作者认为多参数超声可作为前列腺癌风险患者的一线替代检查,尤其当多参数MRI无法进行时。
  • 作者指出联合使用两种影像可提高临床显著前列腺癌的检出率,因各自会漏诊对方检出的癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiparametric MRI of the prostate followed by targeted biopsy is recommended for patients at risk of prostate cancer. However, multiparametric ultrasound is more readily available than multiparametric MRI. Data from paired-cohort validation studies and randomised, controlled trials support the use of multiparametric MRI, whereas the evidence for individual ultrasound methods and multiparametric ultrasound is only derived from case series. We aimed to establish the overall agreement between multiparametric ultrasound and multiparametric MRI to diagnose clinically significant prostate cancer. METHODS: We conducted a prospective, multicentre, paired-cohort, confirmatory study in seven hospitals in the UK. Patients at risk of prostate cancer, aged 18 years or older, with an elevated prostate-specific antigen concentration or abnormal findings on digital rectal examination underwent both multiparametric ultrasound and multiparametric MRI. Multiparametric ultrasound consisted of B-mode, colour Doppler, real-time elastography, and contrast-enhanced ultrasound. Multiparametric MRI included high-resolution T2-weighted images, diffusion-weighted imaging (dedicated high B 1400 s/mm2 or 2000 s/mm2 and apparent diffusion coefficient map), and dynamic contrast-enhanced axial T1-weighted images. Patients with positive findings on multiparametric ultrasound or multiparametric MRI underwent targeted biopsies but were masked to their test results. If both tests yielded positive findings, the order of targeting at biopsy was randomly assigned (1:1) using stratified (according to centre only) block randomisation with randomly varying block sizes. The co-primary endpoints were the proportion of positive lesions on, and agreement between, multiparametric MRI and multiparametric ultrasound in identifying suspicious lesions (Likert score of ≥3), and detection of clinically significant cancer (defined as a Gleason score of ≥4 + 3 in any area or a maximum cancer core length of ≥6 mm of any grade [PROMIS definition 1]) in those patients who underwent a biopsy. Adverse events were defined according to Good Clinical Practice and trial regulatory guidelines. The trial is registered on ISRCTN, 38541912, and ClinicalTrials.gov, NCT02712684, with recruitment and follow-up completed. FINDINGS: Between March 15, 2016, and Nov 7, 2019, 370 eligible patients were enrolled; 306 patients completed both multiparametric ultrasound and multiparametric MRI and 257 underwent a prostate biopsy. Multiparametric ultrasound was positive in 272 (89% [95% CI 85-92]) of 306 patients and multiparametric MRI was positive in 238 patients (78% [73-82]; difference 11·1% [95% CI 5·1-17·1]). Positive test agreement was 73·2% (95% CI 67·9-78·1; κ=0·06 [95% CI -0·56 to 0·17]). Any cancer was detected in 133 (52% [95% CI 45·5-58]) of 257 patients, with 83 (32% [26-38]) of 257 being clinically significant by PROMIS definition 1. Each test alone would result in multiparametric ultrasound detecting PROMIS definition 1 cancer in 66 (26% [95% CI 21-32]) of 257 patients who had biopsies and multiparametric MRI detecting it in 77 (30% [24-36]; difference -4·3% [95% CI -8·3% to -0·3]). Combining both tests detected 83 (32% [95% CI 27-38]) of 257 clinically significant cancers as per PROMIS definition 1; of these 83 cancers, six (7% [95% CI 3-15]) were detected exclusively with multiparametric ultrasound, and 17 (20% [12-31]) were exclusively detected by multiparametric MRI (agreement 91·1% [95% CI 86·9-94·2]; κ=0·78 [95% CI 0·69-0·86]). No serious adverse events were related to trial activity. INTERPRETATION: Multiparametric ultrasound detected 4·3% fewer clinically significant prostate cancers than multiparametric MRI, but it would lead to 11·1% more patients being referred for a biopsy. Multiparametric ultrasound could be an alternative to multiparametric MRI as a first test for patients at risk of prostate cancer, particularly if multiparametric MRI cannot be carried out. Both imaging tests missed clinically significant cancers detected by the other, so the use of both would increase the detection of clinically significant prostate cancers compared with using each test alone. FUNDING: The Jon Moulton Charity Trust, Prostate Cancer UK, and UCLH Charity and Barts Charity.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Grey ADR, Scott R, Shah B, et al. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. Lancet Oncol. 2022. PMID: 35240084. doi:10.1016/S1470-2045(22)00016-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。